IL15 and acute myeloid leukemia: In addition, anti-CD3/CD33 BiTE (AMG-330), anti-CD16/CD33 Bispecific Killer Engagers (BiKE) (known as 1633), anti-CD16/IL-15/CD33 Trispecific Killer Engagers (TriKE) (known as 161533), and anti-CD3/CD123 Dual-Affinity Re-Targeting (DART) antibodies (MGD006) are also in development and under investigation for effectiveness in AML (36, 189).